<DOC>
	<DOCNO>NCT03067493</DOCNO>
	<brief_summary>RAMEC phase II , multi-center , randomize trial safety test . There safety test establish safety tolerability Neo-MASCT treatment ass immune response treatment.The randomize trial ass DFS immune response .</brief_summary>
	<brief_title>RFA Combined With Neo-MASCT Primary HCC : Phase II Trial</brief_title>
	<detailed_description>The safety test recruit 10 patient . Following registration receive 3 cycle Neo-MASCT treatment . Patients see week 1 , week 2 week 4 every cycle . Following safety test , 98 patient randomized trial across 3 recruiting center . All patient treatment arm complete 18 cycle Neo-MASCT treatment . Patients control arm actively monitor randomization . Blood sample immune response test take baseline , cycle 1day 1 3 monthly day 1 subsequent cycle . The planned treatment duration relapse disease , unacceptable toxicity withdrawal consent . The end trial 24 month recruitment last patient .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Aged 1875 year ; 2 . Primary HCC receive RFA initial treatment ; solitary tumour 2.05.0m diameter ; 23 tumour large ≤3.0cm ; without vascular invasion , lymphatic metastasis distant metastasis ( see Appendix 1 diagnosis criterion ) ; Imaging ( enhance CT MRI ) confirm completely tumor necrosis 4 week RFA . 3 . ECOG 0/1 ( Appendix 3 ) ; 4 . ChildPugh score 57 ( Appendix 4 ) ; 5 . A life expectancy 6 month more； 6 . Adequate haematological , liver renal function Neutrophil count ≥1.5 x 109/L ; platelet count &gt; 60 x 109/L ; Haemoglobin concentration≥9.0 g/dL ; Serum albumin≥ 3.0 g/dL ; A total bilirubin le 1.5 time upper limit normal ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less 3 time upper limit normal ; Prothrombin time ≤3s control Serum creatinine concentration 1.5 time upper limit normal range less ; CCR ≥60ml/min 7 . Written inform consent 1 . Pregnant woman , lactate woman woman plan pregnant 2 year ; 2 . Intrahepatic metastasis , tumour thrombosis main trunk main branch portal vein , tumour thrombosis hepatic vein ; 3 . Systematic use potent immunosuppressive agent within 6 month longterm use corticosteroid , cyclosporine A , et al ; 4 . Concomitant HIV HCV infection ; 5 . Concomitant immunodeficiency disease autoimmune disease ( eg . rheumatoid arthritis , Buerger 's disease , multiple sclerosis type I diabetes ) ; 6 . Concomitant malignancy previous malignancy within 5 year enrolment , exclude skin cancer , local prostate cancer cervical carcinoma situ ; 7 . Organ transplant recipient ; 8 . Patients active autoimmune disorder , e.g . autoimmune hepatitis , systemic lupus erythematous etc . ; 9 . Severe dysfunction heart , kidney , organ ; 10 . Severe psychological dysfunction ; 11 . Sensitive cytokine , reagent associate component MASCT ; 12 . Ever participate clinical trial drug within 3 month enrolment ; 13 . Other patient investigator think unsuitable enrol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>